{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:06:21Z","timestamp":1759881981918,"version":"build-2065373602"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The study aimed to analyse changes in the prescribing trends of anxiolytics in Croatia over the past 15\u00a0years, focusing on changes in prescribing patterns and the average cost per defined daily dose (DDD) and to evaluate how frequently patients covered by the Croatian Health Insurance Fund (CHIF) received private prescriptions for anxiolytics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data on total consumption of anxiolytics in Croatia were obtained from two sources: the IMS database and the CHIF database for the period from 2006 to 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The total usage of anxiolytic drugs increased from 61.13 DDD\/1000 in 2006 to 82.78 DDD\/1000 in 2022, an increase of 35.42%, while the financial expenditure in the same period decreased by 15.57%. Diazepam is the anxiolytic drug with the highest prescription rate, with an increase of 67.42%. The highest increase overall was in the total consumption of alprazolam, despite a decrease from 21.22% in 2011 to 16.53% in 2022 in private prescriptions, indicating a substantial increase in prescriptions covered by insurers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite being either not recommended by clinical guidelines or of doubtful efficacy in many cases, prescribing of anxiolytics is common. There is a noticeable increase in anxiolytic drug use in Croatia during the investigated period, while the total financial expenditure has decreased due to price pressure on medications imposed by the national insurer. The high rate of private prescription of anxiolytics is observed. An enhanced national regulatory framework for prescribing anxiolytics in Croatia is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijpp\/riaf051","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:35:03Z","timestamp":1751546103000},"page":"515-520","source":"Crossref","is-referenced-by-count":0,"title":["Trends in publicly and privately prescribed anxiolytics in Croatia: do we need a new regulatory framework"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-4664","authenticated-orcid":false,"given":"Marta Ku\u010dan","family":"\u0160tigli\u0107","sequence":"first","affiliation":[{"name":"Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka , Bra\u0107e Branchetta 20, 51000 Rijeka ,","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tea","family":"Strbad","sequence":"additional","affiliation":[{"name":"Croatian Health Insurance Fund , Margaretska 3, 10 000 Zagreb ,","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belan\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka , Bra\u0107e Branchetta 20, 51000 Rijeka ,","place":["Croatia"]},{"name":"Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka , Kre\u0161imirova 42, 51000 Rijeka ,","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasenka Mr\u0161i\u0107","family":"Pel\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka , Bra\u0107e Branchetta 20, 51000 Rijeka ,","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinko","family":"Vitezi\u0107","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka , Bra\u0107e Branchetta 20, 51000 Rijeka ,","place":["Croatia"]},{"name":"Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka , Kre\u0161imirova 42, 51000 Rijeka ,","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2025100700013387600_ref1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/978-981-32-9705-0_19","article-title":"Current and novel psychopharmacological drugs for anxiety disorders","volume":"1191","author":"Bandelow","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2025100700013387600_ref2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"2025100700013387600_ref3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","article-title":"Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection","volume":"146","author":"Kroenke","year":"2007","journal-title":"Ann Intern Med"},{"key":"2025100700013387600_ref4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/da.10065","article-title":"Generalized anxiety disorder: prevalence, burden, and cost to society","volume":"16","author":"Wittchen","year":"2002","journal-title":"Depress Anxiety"},{"key":"2025100700013387600_ref5","first-page":"20","article-title":"Primary care perspectives on generalized anxiety disorder","volume":"65","author":"Roy-Byrne","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2025100700013387600_ref6","first-page":"183","article-title":"Benzodiazepini: za i protiv","volume":"11","author":"Mimica","year":"2002","journal-title":"Medicus"},{"volume-title":"Benzodiazepini U Suvremenoj Medicini","year":"2001","author":"Jakovljevi\u0107","key":"2025100700013387600_ref7"},{"key":"2025100700013387600_ref8","volume-title":"Klini\u010dka Farmakologija","author":"Franceti\u0107","year":"2014","edition":"2."},{"volume-title":"WHO Collaborating Centre for Drug Statistics Methodol- Ogy. Purpose of the ATC\/DDD System","key":"2025100700013387600_ref9"},{"key":"2025100700013387600_ref10"},{"key":"2025100700013387600_ref11"},{"key":"2025100700013387600_ref12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult Pharm"},{"key":"2025100700013387600_ref13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000524400","article-title":"Benzodiazepines remain important therapeutic options in psychiatric practice","volume":"91","author":"Dubovsky","year":"2022","journal-title":"Psychother Psychosom"},{"key":"2025100700013387600_ref14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/7854_2015_425","article-title":"Benzodiazepines","volume":"34","author":"Nielsen","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"2025100700013387600_ref15","first-page":"90","article-title":"Side effects of treatment with benzodiazepines","volume":"22","author":"Uzun","year":"2010","journal-title":"Psychiatr Danub"},{"key":"2025100700013387600_ref16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/0023210-200923010-00002","article-title":"Withdrawing benzodiazepines in primary care","volume":"23","author":"Lader","year":"2009","journal-title":"CNS Drugs"},{"key":"2025100700013387600_ref17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11920-015-0642-5","article-title":"Withdrawing Benzodiazepines in Patients With Anxiety Disorders","volume":"18","author":"Lader","year":"2016","journal-title":"Curr Psychiatry Rep"},{"key":"2025100700013387600_ref18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14737167.2018.1507820","article-title":"The benzodiazepine nation of Croatia: an observational, comparative study of psychotropic drug utilization between Croatia and Sweden 2014\u20132015","volume":"18","author":"Poto\u010dnjak","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025100700013387600_ref19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1007\/s11096-019-00915-2","article-title":"Outpatient benzodiazepine utilization in Croatia: drug use or misuse","volume":"41","author":"Dela\u0161 A\u017edaji\u0107","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"2025100700013387600_ref20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bcpt.13811","article-title":"Use of benzodiazepines and benzodiazepine-related drugs in the Nordic countries between 2000 and 2020","volume":"132","author":"H\u00f8jlund","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025100700013387600_ref21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1055\/a-0961-2371","article-title":"Benzodiazepine und Z-Substanzen \u2013 Analyse der kassen\u00e4rztlichen Verschreibungen von 2006 bis 2015 [Benzodiazepines and Z-Drugs - Analyses of Ambulatory Prescriptions from 2006 to 2015]","volume":"46","author":"Verthein","year":"2019","journal-title":"Psychiatr Prax"},{"key":"2025100700013387600_ref22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-023-03515-2","article-title":"Factors associated with long-term benzodiazepine and Z-drug use across the lifespan and 5-year temporal trajectories among incident users: a Swedish nationwide register-based study","volume":"79","author":"Isomura","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2025100700013387600_ref23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jad.2022.11.068","article-title":"Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia","volume":"323","author":"Tiger","year":"2023","journal-title":"J Affect Disord"},{"key":"2025100700013387600_ref24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/jech-2021-216732","article-title":"Prescription of anxiolytics, sedatives, hypnotics and antidepressants in outpatient, universal care during the COVID-19 pandemic in Portugal: a nationwide, interrupted time-series approach","volume":"76","author":"Estrela","year":"2022","journal-title":"J Epidemiol Community Health"},{"key":"2025100700013387600_ref25","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.3390\/ijerph19084782","article-title":"Consumption of psychiatric drugs in primary care during the COVID-19 pandemic","volume":"19","author":"Gonz\u00e1lez-L\u00f3pez","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025100700013387600_ref26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12889-023-15360-0","article-title":"Psychotropic consumption before and during COVID-19 in Asturias, Spain","volume":"23","author":"Garc\u00eda","year":"2023","journal-title":"BMC Public Health"},{"key":"2025100700013387600_ref27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/fampra\/cmab143","article-title":"Discontinuation of chronic benzodiazepine use in primary care: a nonrandomized intervention","volume":"39","author":"Fernandes","year":"2022","journal-title":"Fam Pract"},{"key":"2025100700013387600_ref33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/pds.5536","article-title":"Role of private prescriptions in the long-term use of benzodiazepines and Z-drugs: a patient-related follow-up study","volume":"32","author":"Grimmsmann","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025100700013387600_ref28"},{"key":"2025100700013387600_ref29","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s00115-014-4016-8","article-title":"Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept: Verbrauch zwischen 1993 und 2012","volume":"85","author":"Hoffmann","year":"2014","journal-title":"Nervenarzt."},{"key":"2025100700013387600_ref30"},{"key":"2025100700013387600_ref31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13011-020-00260-y","article-title":"Benzodiazepines in the oral fluid of Spanish drivers","volume":"15","author":"Herrera-G\u00f3mez","year":"2020","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025100700013387600_ref32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.forsciint.2012.08.012","article-title":"Prevalence of psychoactive substances, alcohol, illicit drugs, and medicines in Spanish drivers: a roadside study","volume":"223","author":"G\u00f3mez-Taleg\u00f3n","year":"2012","journal-title":"Forensic Sci Int"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/33\/5\/515\/63661385\/riaf051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/33\/5\/515\/63661385\/riaf051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:01:41Z","timestamp":1759809701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/33\/5\/515\/8185431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7,3]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riaf051","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"type":"print","value":"0961-7671"},{"type":"electronic","value":"2042-7174"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,7,3]]}}}